GB2386120B - Differentiated cells suitable for human therapy - Google Patents

Differentiated cells suitable for human therapy

Info

Publication number
GB2386120B
GB2386120B GB0313389A GB0313389A GB2386120B GB 2386120 B GB2386120 B GB 2386120B GB 0313389 A GB0313389 A GB 0313389A GB 0313389 A GB0313389 A GB 0313389A GB 2386120 B GB2386120 B GB 2386120B
Authority
GB
United Kingdom
Prior art keywords
differentiated cells
cells suitable
human therapy
therapy
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0313389A
Other languages
English (en)
Other versions
GB2386120A (en
GB0313389D0 (en
Inventor
Joseph D Gold
Jane S Lebkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of GB0313389D0 publication Critical patent/GB0313389D0/en
Publication of GB2386120A publication Critical patent/GB2386120A/en
Application granted granted Critical
Publication of GB2386120B publication Critical patent/GB2386120B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0313389A 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy Expired - Fee Related GB2386120B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25344300P 2000-11-27 2000-11-27
US25335700P 2000-11-27 2000-11-27
US09/783,203 US6576464B2 (en) 2000-11-27 2001-02-13 Methods for providing differentiated stem cells
PCT/US2001/044309 WO2002042445A2 (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy

Publications (3)

Publication Number Publication Date
GB0313389D0 GB0313389D0 (en) 2003-07-16
GB2386120A GB2386120A (en) 2003-09-10
GB2386120B true GB2386120B (en) 2005-03-09

Family

ID=27400669

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0313389A Expired - Fee Related GB2386120B (en) 2000-11-27 2001-11-26 Differentiated cells suitable for human therapy

Country Status (11)

Country Link
US (4) US6576464B2 (enExample)
EP (1) EP1337632B1 (enExample)
JP (1) JP2004523217A (enExample)
KR (1) KR20030081334A (enExample)
CN (2) CN101928692A (enExample)
AU (2) AU3768102A (enExample)
CA (1) CA2434760C (enExample)
ES (1) ES2544942T3 (enExample)
GB (1) GB2386120B (enExample)
IL (2) IL155695A0 (enExample)
WO (1) WO2002042445A2 (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
BR0014864A (pt) * 1999-10-15 2002-11-19 Advanced Cell Tech Inc Métodos de produzir células progenitoras diferenciadas e células tronco embriÈnicas defeituosas em linhagem
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6921665B2 (en) * 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
CA2478681A1 (en) * 2001-10-22 2003-05-01 University Of Rochester Telomerase interference
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US7514075B2 (en) 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US7585670B2 (en) 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
EP1463803B1 (en) 2001-12-07 2018-02-14 Asterias Biotherapeutics, Inc. Hematopoietic cells from human embryonic stem cells
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US7771716B2 (en) * 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US7595043B2 (en) * 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US9597395B2 (en) * 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US20030161816A1 (en) 2001-12-07 2003-08-28 Fraser John K. Systems and methods for treating patients with processed lipoaspirate cells
US20050170506A1 (en) * 2002-01-16 2005-08-04 Primegen Biotech Llc Therapeutic reprogramming, hybrid stem cells and maturation
US20050090004A1 (en) * 2003-01-16 2005-04-28 Sayre Chauncey B. Stem cell maturation for all tissue lines
US20030134422A1 (en) * 2002-01-16 2003-07-17 Sayre Chauncey Bigelow Stem cell maturation for all tissue lines
WO2003066839A1 (en) * 2002-02-05 2003-08-14 Rappaport Family Institute For Research In The Medical Sciences Lineage committed stem cells selected for telomerase promoter activity
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003231950A1 (en) * 2002-05-30 2003-12-19 Celgene Corporation Modulating cell differentiation and treating myeloproliferative disorders with JNK/MKK inhibitors
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US20050014116A1 (en) * 2002-11-27 2005-01-20 Reid Gregory S. Testing information comprehension of contact center users
US20040214324A1 (en) * 2002-12-09 2004-10-28 Ole Isacson Dopaminergic neurons differentiated from embryonic cells for treating neurodegenerative diseases
EP2457999B1 (en) 2002-12-16 2018-10-17 Technion Research & Development Foundation Ltd. Culture medium for pluripotent stem cells
US20060211111A1 (en) * 2002-12-18 2006-09-21 Maisam Mitalipova Compositions and methods for neural cell production and stabilization
US7153650B2 (en) 2003-03-13 2006-12-26 Geron Corporation Marker system for preparing and characterizing high-quality human embryonic stem cells
WO2004104184A1 (ja) * 2003-05-20 2004-12-02 Riken 内胚葉系幹細胞の調製
WO2004113515A2 (en) 2003-06-20 2004-12-29 Axiogenesis Ag Tissue modeling in embryonic stem (es) cell system
AR046076A1 (es) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida
US20050054100A1 (en) * 2003-09-08 2005-03-10 Rennard Stephen I. Methods for fibroblast differentiation
JP2007512838A (ja) 2003-12-01 2007-05-24 インヴィトロジェン コーポレーション 組換え部位を含む核酸分子およびその使用方法
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG188122A1 (en) * 2004-01-23 2013-03-28 Advanced Cell Tech Inc Improved modalities for the treatment of degenerative diseases of the retina
WO2005079849A2 (en) * 2004-02-25 2005-09-01 Zgene A/S Compounds for enhanced cancer therapy
US20050277124A1 (en) 2004-06-10 2005-12-15 White Steven M Cardiac conduction system cells and uses thereof
WO2006014159A2 (en) * 2004-07-01 2006-02-09 Macropore Biosurgery Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
EP1812556A4 (en) * 2004-10-05 2011-02-02 Univ Georgia NEURONAL PRECURSORS OF FEEDER-FREE HUMAN EMBRYONIC STEM CELL CULTURE
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
US20060148080A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Methods for supporting and producing human cells and tissues in non-human mammal hosts
WO2006126972A1 (en) * 2005-05-27 2006-11-30 Agency For Science, Technology And Research Method of delivering nucleic acid molecules into embryonic stem cells using baculoviral vectors
ES2524996T3 (es) 2005-06-16 2014-12-16 Ramot At Tel Aviv University Ltd. Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC
AU2006262369B2 (en) 2005-06-22 2012-07-05 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
EP1962719A4 (en) 2005-08-29 2011-05-04 Technion Res And Dev Of Foundation Ltd MEDIA FOR BREEDING STEM CELLS
CN1966080B (zh) * 2005-11-17 2011-06-08 李凌松 一种治疗老年痴呆症、帕金森病的神经干细胞注射液
WO2007066338A1 (en) * 2005-12-08 2007-06-14 Ramot At Tel Aviv University Ltd. Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases
WO2007139551A1 (en) * 2006-05-30 2007-12-06 Cytori Therapeutics, Inc. Systems and methods for manipulation of regenerative cells from adipose tissue
WO2008013863A2 (en) * 2006-07-26 2008-01-31 Cytori Therapeutics, Inc. Generation of adipose tissue and adipocytes
DK3441459T3 (da) 2006-08-02 2021-06-07 Technion Res & Dev Foundation Fremgangsmåder til ekspansion af embryonale stamceller i en suspensionskultur
US20080081370A1 (en) * 2006-09-28 2008-04-03 Peiman Hematti Directed differentiation of human embryonic stem cells into mesenchymal/stromal cells
ES2764473T3 (es) 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
US8501474B2 (en) * 2007-10-15 2013-08-06 Technion Research & Development Foundation Limited Methods of generating embryoid bodies and uses of same
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
WO2010114136A1 (ja) * 2009-03-30 2010-10-07 第一三共株式会社 多能性幹細胞及び心筋細胞以外の分化細胞に対する細胞死誘導方法
CA2760574C (en) * 2009-05-01 2020-10-27 Cytori Therapeutics, Inc. Device and method for preparing tissue for an adipose graft
WO2010151782A1 (en) * 2009-06-25 2010-12-29 Geron Corporation Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes
EP2499236B1 (en) 2009-11-12 2020-01-01 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CN102933704A (zh) 2010-04-08 2013-02-13 爱丁堡大学管理处 软骨祖细胞、用于细胞衍生的方案和其用途
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
JP6037393B2 (ja) * 2011-03-29 2016-12-07 国立大学法人 鹿児島大学 幹細胞における腫瘍化原因細胞の除去方法
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
WO2013134015A2 (en) 2012-03-05 2013-09-12 Wake Forest University Health Sciences Non-viral episomal suicide construct
KR102423106B1 (ko) 2013-06-11 2022-07-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
WO2016100930A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived b cells and methods of use thereof
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CN109563482A (zh) 2016-06-10 2019-04-02 埃尔瓦有限公司 含表达异于分泌免疫球蛋白和细胞溶解功能的膜免疫球蛋白的b淋巴细胞系的组合物和方法
KR102106895B1 (ko) * 2017-02-16 2020-05-07 고려대학교 산학협력단 골재생 효능이 우수한 골질환 예방 또는 치료용 조성물
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3692139B1 (en) 2017-10-03 2024-11-06 SDF BioPharma Inc. Treating diabetes with genetically modified beta cells
AU2018370029B2 (en) 2017-11-15 2024-11-07 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN119709646A (zh) * 2024-09-14 2025-03-28 青岛阿尔泰基因工程有限公司 一种治疗颅咽管瘤的慢病毒及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019469A1 (en) * 1997-10-09 1999-04-22 Biotransplant, Inc. Porcine stem cells comprising a marker under an oct-4 promoter
WO1999020741A1 (en) * 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO1999045100A1 (en) * 1998-03-02 1999-09-10 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Embryonic or stem-like cell lines produced by cross-species nuclear transplantation
WO2000046355A2 (en) * 1999-02-04 2000-08-10 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
WO2001051616A2 (en) * 2000-01-11 2001-07-19 Geron Corporation Techniques for growth and differentiation of human pluripotent stem cells
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959313A (en) 1987-06-22 1990-09-25 The Jackson Laboratory Cellular enhancer for expressing genes in undifferentiated stem cells
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5639613A (en) 1992-05-13 1997-06-17 Board Of Regents, University Of Texas System Methods for cancer diagnosis and prognosis
AU678988B2 (en) 1992-07-27 1997-06-19 California Institute Of Technology Mammalian multipotent neural stem cells
US5693482A (en) 1992-07-27 1997-12-02 California Institute Of Technology Neural chest stem cell assay
US5766948A (en) 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6015671A (en) * 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
US5489304A (en) 1994-04-19 1996-02-06 Brigham & Women's Hospital Method of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft
US5639618A (en) 1994-05-13 1997-06-17 Plurion, Inc. Method of isolating a lineage specific stem cell in vitro
GB9417831D0 (en) 1994-09-05 1994-10-26 Biotech & Biolog Scien Res Biological manipulation
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
GB9505663D0 (en) 1995-03-21 1995-05-10 Stringer Bradley M J Genetically modified neural cells
US6117985A (en) 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
GB9526509D0 (en) 1995-12-23 1996-02-28 Univ Dundee Gene control
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
WO1997032025A1 (en) 1996-03-01 1997-09-04 Regents Of The University Of Minnesota Method for selective engraftment of drug-resistant hematopoietic stem cells
EP0929328A4 (en) 1996-08-26 2000-08-02 Hemasure Inc PROCESS FOR REMOVING TUMOR CELLS FROM PRODUCTS CONTAINING STEM CELLS CONTAMINATED BY TUMOR CELLS
FI990655A7 (fi) 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
GB9621383D0 (en) 1996-10-14 1996-12-04 Roslin Inst Edinburgh Transgene expression
EP0991321A4 (en) 1997-02-05 2002-01-30 Gen Hospital Corp TOLERANCE TO ANTIGENT NATURAL ANTIBODIES
AU6346898A (en) 1997-03-06 1998-09-22 University Of Massachusetts Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
DE19727962A1 (de) 1997-07-02 1999-01-14 Juergen Hescheler Fluoreszierende Proteine als zelltypspezifische Reporter
AU9200298A (en) 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in stem cells
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
WO1999027076A1 (en) 1997-11-25 1999-06-03 Arc Genomic Research Pluripotent embryonic stem cells and methods of obtaining them
DE19757984A1 (de) 1997-12-24 1999-07-01 Bayer Ag Regulatorische DNA-Sequenzen aus der 5'-Region vom Gen der humanen katalytischen Telomerase-Untereinheit udn deren diagnostische und therapeutische Verwendung
GB9811859D0 (en) 1998-06-02 1998-07-29 Biotech & Biolog Scien Res Biological manipulation
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
BR9914465A (pt) 1998-09-29 2001-10-09 Gamida Cell Ltd Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
DK1226233T3 (da) 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
US6921665B2 (en) 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
CA2430653A1 (en) 2000-11-27 2002-08-08 Yissum Research Development Company Of The Hebrew University In Jerusalem Transfection of human embryonic stem cells
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019469A1 (en) * 1997-10-09 1999-04-22 Biotransplant, Inc. Porcine stem cells comprising a marker under an oct-4 promoter
WO1999020741A1 (en) * 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
WO1999045100A1 (en) * 1998-03-02 1999-09-10 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Embryonic or stem-like cell lines produced by cross-species nuclear transplantation
WO2000046355A2 (en) * 1999-02-04 2000-08-10 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
WO2001051616A2 (en) * 2000-01-11 2001-07-19 Geron Corporation Techniques for growth and differentiation of human pluripotent stem cells
WO2001088104A2 (en) * 2000-05-17 2001-11-22 Geron Corporation Neural progenitor cell populations

Also Published As

Publication number Publication date
ES2544942T3 (es) 2015-09-07
JP2004523217A (ja) 2004-08-05
US6576464B2 (en) 2003-06-10
CA2434760A1 (en) 2002-05-30
KR20030081334A (ko) 2003-10-17
AU2002237681B2 (en) 2007-03-22
CA2434760C (en) 2013-09-24
US20130273651A1 (en) 2013-10-17
WO2002042445A3 (en) 2003-01-16
GB2386120A (en) 2003-09-10
WO2002042445A2 (en) 2002-05-30
IL155695A0 (en) 2003-11-23
US8426198B2 (en) 2013-04-23
GB0313389D0 (en) 2003-07-16
CN1478145A (zh) 2004-02-25
IL155695A (en) 2007-10-31
AU3768102A (en) 2002-06-03
CN101928692A (zh) 2010-12-29
EP1337632B1 (en) 2015-05-20
EP1337632A2 (en) 2003-08-27
US20020098582A1 (en) 2002-07-25
US20060134782A1 (en) 2006-06-22
US20030040111A1 (en) 2003-02-27
US9023645B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
GB2386120B (en) Differentiated cells suitable for human therapy
GB0028429D0 (en) Therapy
GB0016787D0 (en) Compounds useful in therapy
GB9912411D0 (en) Compounds useful in therapy
GB9912413D0 (en) Compounds useful in therapy
GB9907243D0 (en) Therapy
IL155433A0 (en) Treatment of t cell disorders
GB9912410D0 (en) Compounds useful in therapy
GB0001710D0 (en) Therapeutic treatment
GB9912416D0 (en) Compounds useful in therapy
GB9912415D0 (en) Compounds useful in therapy
AU2096002A (en) Therapeutic treatment
EP1194439A4 (en) EAG2 OF HUMAN ORIGIN
GB9911238D0 (en) Therapeutic use
GB9906130D0 (en) Compounds for use in therapy
GB0014046D0 (en) Compounds useful in therapy
GB0026967D0 (en) Stem cell therapy
GB0020942D0 (en) Therapy
GB0023422D0 (en) Therapy
GB0026945D0 (en) Therapy
GB0029577D0 (en) Therapy
AU9481201A (en) Human nedd-1
GB9912184D0 (en) Therapeutic use
GB9921953D0 (en) Therapeutic use
GB9913350D0 (en) Therapeutic use

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20140410 AND 20140416

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20151126